A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with earlystage breast cancer

This article has no abstract
Epistemonikos ID: 64fd752c5c1ae22afeb4be82c9aafb1bade282fb
First added on: Feb 07, 2025